Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : to Hold Settlement Talks for Some Glyphosate Suits --Reuters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/06/2019 | 11:59am EST

--Two upcoming trials in California concerning the ingredient glyphosate in Bayer AG's (BAYRY) weed killers have been delayed for settlement talks, Reuters reports Friday.

--Bayer said the postponements will allow it to "engage constructively in the mediation process," according to the report.

--Bayer is facing suits from plaintiffs claiming its Roundup herbicides caused cancer.

Full story: https://www.reuters.com/article/us-bayer-glyphosate/bayer-reaches-agreement-to-postpone-more-glyphosate-lawsuits-for-settlement-talks-idUSKBN1YA1QO

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
09:57aBAYER : confirms leading international position as a sustainable company taking ..
AQ
01/20BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
01/20Japan, U.S. lead survey's corporate climate change action 'A List'
RE
01/18Drugmakers slash prices to be eligible for China's bulk-buy program
RE
01/17Bayer could be close to Roundup settlement, mediator says
RE
01/17EUROPE : European shares touch all-time peak on cross-Atlantic trade optimism
RE
01/17A flurry of news in the global auto industry
01/16BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
01/16BAYER : and WuXi Biologics enter into an agreement on a Leverkusen drug product ..
PU
01/15China's 'market condition' caveat on U.S. ag purchases adds to trade deal dou..
RE
More news
Financials (EUR)
Sales 2019 43 974 M
EBIT 2019 7 853 M
Net income 2019 3 106 M
Debt 2019 35 649 M
Yield 2019 3,77%
P/E ratio 2019 24,5x
P/E ratio 2020 16,0x
EV / Sales2019 2,50x
EV / Sales2020 2,29x
Capitalization 74 173 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 81,28  €
Last Close Price 75,50  €
Spread / Highest target 62,9%
Spread / Average Target 7,66%
Spread / Lowest Target -48,7%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Florian Schwalbach Head-Information Technology & Business Services
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG3.69%82 204
JOHNSON & JOHNSON2.26%392 596
ROCHE HOLDING AG4.44%289 068
MERCK AND COMPANY0.02%231 608
PFIZER3.39%224 187
NOVARTIS0.96%216 654